Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with ...

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

It's a building around, it is a diversification ... But I think we have great teams within Biogen and we are able to really dissect these data sets to see whether we have enough confidence ...

Meanwhile, fellow Swiss company Novartis will no longer use diverse panels in its hiring process for U.S.-based employees, ...

In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.

Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST] ...

represents a key asset in Biogen’s late-stage immunology portfolio “Building upon the promising results from the Phase 2 study, which demonstrated felzartamab’s first-in-class potential ...

“Building upon the promising results from the ... its clinical development,” said Travis Murdoch, Head of HI-Bio at Biogen. “Losing a kidney after receiving a long-awaited transplant is ...

There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.